Drug shortages adding to workloads at Irish pharmacies
Irish Pharmacy Union
(IPU).
The IPU said the medicine shortages, largely driven by demand for treatments such as hormone replacement therapy, GLP-1 agonists for weight loss such as
Ozempic
and treatments for
ADHD
, are increasingly negatively affecting patient outcomes.
According to the IPU survey, pharmacists and their teams are now spending more than six hours each week managing shortages, up from between five and 10 hours a month in 2018.
The majority of respondents (95 per cent) reported contacting prescribers regularly to source alternatives with 83 per cent saying they are borrowing stock from other pharmacies, described by the IPU as 'labour-intensive efforts that often go unrecognised and unremunerated'.
READ MORE
The survey of more than 300 community pharmacists showed a persistent high rate of medicine shortages, with 57 per cent of respondents encountering 40 or more shortages in the past four months.
The poll carried out in March and April saw 57 per cent also say shortages had 'significantly increased,' and while this was down from 82 per cent in 2024, most respondents (78 per cent) expect the problem to worsen over the coming year.
Some 71 per cent reported negative patient outcomes due to the shortages, up from 66 per cent last year, with a further 82 per cent believing pharmacists should have greater clinical discretion in sourcing generic alternatives.
[
Plan to make pharmacies display dispensing fees will not make 'a blind bit of difference'
Opens in new window
]
While medicine shortages are largely 'multifactorial,' current shortages are largely driven by demand, according to Clare Fitzell, the IPU's secretary general.
'When a medicine is in short supply, this can interrupt treatment, something which can be a cause of distress for patients and their families.
'Whilst medicine shortages may be a feature of modern health systems, we need to ensure that the impact of such shortages is minimised to the greatest extent possible,' she said.
Ms Fitzell said the survey findings highlight a profession under pressure, saying: 'This is unsustainable and requires urgent, system-wide solutions.'
The IPU is calling on the
Department of Health
to expedite the Health Miscellaneous Provisions Bill 2024, which will facilitate the substitution of medicines by pharmacists in the case of shortages without needing to revert to the prescriber.
The medicine substitution protocols, which will speed up the process, will also benefit patients and prescribers, Ms Fitzell said.
While describing as 'significant' a commitment made in the programme for government to support pharmacists to adopt a proactive approach to manage shortages, Ms Fitzell said: 'This now needs to be progressed at pace.'
The issue is due to be discussed at the Irish Pharmacy Union conference on Saturday, which Minister for Health
Jennifer Carroll MacNeill
is expected to attend.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
2 hours ago
- Irish Times
Environment watchdog recommends mandating registration of private drinking water supplies
The Environmental Protection Agency (EPA) has called on the Government to urgently introduce mandatory registration for all private drinking water supplies because of ongoing contamination and the absence of accurate data on people getting their water from such sources. In its report on private water supplies for 2024 published on Tuesday, it highlights the total number of small private supplies remains unknown as there is no legal obligation to register, while unregistered supplies are not monitored by local authorities – despite a worsening problem in the sector. Water quality in private water supplies 'is not as good as public water supplies', with the number of private group schemes failing to meet standards in 2024 at 24; up from 13 in 2022. More than 370 private group schemes supply drinking water to 193,000 people across rural communities. In addition, many businesses and public facilities source water from their own private wells – known as small private supplies. Almost 1,700 small private supplies are registered with local authorities, but many more are not. These include supplies serving schools, nursing homes, sports clubs and self-catering accommodation. EPA director Micheál Lehane said: 'Without registration and subsequent monitoring by local authorities, consumers are unaware of the potential health risk they may be exposed to.' In the interim, the EPA said private suppliers should register with local authorities 'so all proper safety checks can be carried out on their supply'. Meeting standards is a minimum requirement in providing safe water and failures indicate lack of proper disinfection. Six schemes had repeat failures over two consecutive years and five of these are on long-term boil water notices. failures were recorded in 51 small private supplies monitored by local authorities. Programme manager at the EPA office of environmental monitoring Noel Byrne said: ' compliance has declined with almost double the number of private supplies failing in 2024 compared to 2022.' In 2024, 19 private group schemes supplying 21,800 people failed the standard for Trihalomethanes, which can form when organic matter in water reacts with chlorine disinfectant – long-term exposure poses a health risk.
Irish Times
5 hours ago
- Irish Times
Inquiry begins into historical use of anti-epileptic drug and effects on pregnant women
The historical licensing and use of the anti-epileptic drug sodium valproate for women of childbearing age will be examined as part of an inquiry that started its work on Tuesday. Mothers of children diagnosed with foetal valproate spectrum disorder (FVSD) have long called for a public inquiry to investigate why they were not warned about the risks of taking the drug while pregnant . FVSD is caused by exposure in the womb to valproic acid, which is the key ingredient in sodium valproate, better known in Ireland as Epilim. An Irish Medical Journal study published in 2021 said diagnosing the condition was 'difficult' due to the lack of any specific diagnostic test or biomarker. READ MORE However, it said dysmorphic facial features, neural tube defects, congenital heart disease and cleft lip were among the most commonly associated characteristics. The study noted that Irish public health data suggested 3,126 babies were potentially exposed to sodium valproate before birth between 1975 and 2015. Minister for Health Jennifer Carroll MacNeill said the inquiry would give people directly affected by sodium valproate an 'opportunity to have their voices heard'. She welcomed the commencement of the inquiry, which was announced last year by her predecessor, Stephen Donnelly. She said she recently met the Organisation Anticonvulsant Syndromes Ireland (OACS Ireland), a campaign group dedicated to supporting and advocating for families affected by foetal anticonvulsant syndrome. 'I know this is an important day for them and the families they represent,' Ms Carroll MacNeill said. 'I have every confidence that the chair will conduct an independent and fair inquiry and finally get answers for those affected and their families.' The inquiry, involving three distinct phases, is chaired by barrister Bríd O'Flaherty. The Department of Health said it envisaged she would spend 12 to 18 months conducting an 'independent, fair and rigorous process'. The first phase will establish a timeline for the use of sodium valproate in women of childbearing potential in the State, including information on regulation, prescribing, dispensing and safety information issued. The inquiry will document the evolution of the drug's regulation and practices around its control. The second phase will focus on oral statements from people diagnosed with FVSD, their mothers and other family members. The final strand will assess the health service's capacity to respond to safety issues related to the use of anti-seizure medications in women of child-bearing potential.
Irish Times
5 hours ago
- Irish Times
Settlement of €1.9m for boy who suffered ‘severe personal injury' at Portlaoise hospital
A boy born in Midland Regional Hospital in Portlaoise who was allegedly delivered after a delayed Caesarean section amid rowing doctors and who suffered 'severe personal injury' has had a €1.9 million settlement in his favour approved by the High Court . The now 16-year-old was born on January 30th, 2009, at the hospital, which has been subject to investigation over patient safety. His mother sued the HSE on behalf of her son for breach of statutory duty – alleged medical negligence – to adequately provide medical services to her and her son in 2009 at the Co Laois hospital. It was submitted that she was due to give birth around January 25th, 2009, and had attended all of her antenatal appointments, culminating with a clinic at the hospital on January 29th, 2009, when no 'significant abnormal conditions in relation to the pregnancy were present'. READ MORE She was admitted to the hospital on January 30th, 2009, five days after her due date, but had 'slow and irregular' pain. A cardiotocography trace (CTG) was carried out and was found to be 'abnormal', as the unborn baby displayed 'frequent decelerations' in his heart rate. However, despite the abnormal readings, the CTG was discontinued. A second CTG was carried out at 8.45am the same morning that showed decelerations and abnormalities up to around 12.30pm. It was claimed that then a syntocinon treatment – an injection involving the drug oxytocin – was administered to augment labour. It was claimed that the readings from the CTG were not reproduced in a legible fashion and were difficult to interpret. A decision was made to deliver the boy by emergency Caesarean section and the boy was born at 1.36pm, allegedly 80 minutes after a decision to perform the Caesarean was made – 50 minutes outside the usual time frame. It was claimed the boy suffered 'extreme difficulties' with breathing, due to hypoxia, and that there was a delay in his resuscitation. In addition, an altercation between members of the hospital staff occurred during the attempts at resuscitation of the plaintiff, it was alleged. During a second attempt at intubation, a doctor was interrupted by an anaesthetic doctor without invitation who attempted to force an oxygen mask on the child, it was claimed. It was alleged that the anaesthetist 'brushed aside' the attending doctor and raised his voice, shouting 'for f*** sake just bag him'. The doctor was eventually able to drain meconium – a baby's first stool – from the child through suction, after which safe intubation was performed. The doctor, it was submitted, was 'considerably interrupted in his attempts to intubate and resuscitate the plaintiff by actions of the anaesthetist doctor'. In the aftermath of his birth, the plaintiff was noted as being in pain, jaundiced, vomiting with streaks of blood, having hypoxic metabolic acidosis, high blood pressure and in need of ventilation. The plaintiff spent 11 days in intensive care, and an MRI scan showed the plaintiff's kidney and brain had an infarct resulting in 'severe personal injuries', it was claimed. At the High Court on Tuesday Mr Justice Paul Coffey was told by John Healy SC, instructed by David O'Malley of Callan Tansey solicitors, for the plaintiff that a final settlement of €1.9 million for breaches of duty by the defendant, albeit without an admission of liability, could be recommended to the court for what he said was the boy's 'turbulent' introduction to the world. Mr Justice Coffey approved the settlement and addressed the boy, who was present in court, saying he was pleased to see him 'looking so well and I wish you all the best for the future'. Reacting to the settlement, solicitor David O'Malley, in a statement on behalf the family, said: 'The family welcomes the settlement and for the security it will provide.' He added: 'It truly is a second-tier maternity system outside of The Pale. 'The family echoes calls by advocate groups to urgently review maternity care in Ireland. One cannot think of a more important right than the right to breathe and be protected at birth.'
